Table 2.
Summary of AEs (Safety Population)a
| Event, n (%) |
Glecaprevir/Pibrentasvir (N = 100) |
|---|---|
| Any AE | 85 (85) |
| Any AE possibly related to DAAs | 48 (48) |
| Any AE with grade 3 severity or greater | 12 (12) |
| Any DAA‐related AE with grade 3 severity or greater | 3 (3) |
| Any SAE | 8 (8) |
| Any SAE possibly related to DAAs | 2 (2) |
| Any AE leading to treatment discontinuation | 1 (1) |
| Death | 0 |
| AEs occurring in ≥10% of patients | |
| Fatigue | 22 (22) |
| Headache | 22 (22) |
| Nausea | 12 (12) |
| Pruritus | 12 (12) |
| Diarrhea | 10 (10) |
a
MedDRA version 19.1 was used for reporting of AEs.